Acute myelogenous leukemia (AML) is a hematopoietic neoplasm that primarily affects older adults. Despite scientific advances into the epidemiologic, genetic, and biological features of AML, this disease remains fatal to the majority of patients, particularly older individuals.
Methods
We review the biologic and clinical characteristics of AML in the elderly and the treatment options that have emerged for them during the past several years.
Results
Several biologic features of AML differ between older and younger individuals. Older patients often have disease that expresses multidrug resistance phenotype and cytogenetic abnormalities, which may be responsible in large part for the poor outcomes observed in older-aged subgroups. Traditional cytotoxic chemotherapy is associated with a low complete response rate and a high treatment-related mortality in older patients, which explains in part the poorer outcomes in cohorts over 60 years of age. Research into the pathophysiology of AML has revealed an abundance of intracellular signaling events that govern proliferation and survival of the malignant cell. Such discoveries have promoted recognition of new molecular and antigenic targets (eg, Flt-3 kinase, Ras, CD33 antigen) to which therapeutic development may be aimed.
Conclusions
New therapies directed against these unique targets may add to the current arsenal of antileukemic regimens and improve response rates and survival in older patients.
References
1.
YancikR.Cancer burden in the aged: an epidemiologic and demographic overview. Cancer.1997; 80: 1273–1283.
2.
TaylorP.R., ReidM.M., StarkA.N.De novo acute myeloid leukaemia in patients over 55 years old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group. Leukemia.1995; 9: 231–237.
3.
JemalA., MurrayT., SamuelsA.Cancer statistics, 2003. CA Cancer J Clin.2003; 53: 5–26.
4.
RiesL.A.G., EisnerM.P., KosaryC.L.SEER Cancer Statistics Review, 1973-1999.Bethesda, Md: National Cancer Institute. Available at http://seer.cancer.gov/csr/1973_1999/. Accessed August 12, 2003.
SandlerD.P.Epidemiology of acute myelogenous leukemia. Semin Oncol.1987; 14: 359–364.
7.
Pedersen-BjergaardJ., PhilipP., LarsenS.O.Therapy-related myelodysplasia and acute myeloid leukemia: cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia.1993; 7: 1975–1986.
8.
GrimwadeD., WalkerH., OliverF.The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood.1998; 92: 2322–2333.
9.
BloomfieldC.D., LawrenceD., ByrdJ.C.Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res.1998; 58: 4173–4179.
10.
GrimwadeD., WalkerH., HarrisonG.The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood.2001; 98: 1312–1320.
11.
LeithC.P., KopeckyK.J., GodwinJ.Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood.1997; 89: 3323–3329.
12.
HiddemannW., KernW., SchochC.Management of acute myeloid leukemia in elderly patients. J Clin Oncol.1999; 17: 3569–3576.
13.
SchochC., HaferlachT., HaaseD.Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol.2001; 112: 118–126.
14.
WahlinA., MarkevarnB., GolovlevaI.Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol.2001; 115: 25–33.
15.
ByrdJ., LawrenceD., ArthurD.Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. Clin Cancer Res.1998; 4: 1235–1241.
16.
GreeneM.H., HarrisE.L., GershensonD.M.Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med.1986; 105: 360–367.
17.
Pedersen-BjergaardJ., ErsbollJ., SorensenH.M.Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas: comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med.1985; 103: 195–200.
18.
PuiC.H., RibeiroR.C., HancockM.L.Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med.1991; 325: 1682–1687.
19.
LevineE.G., BloomfieldC.D.Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol.1992; 19: 47–84.
20.
GajewskiJ.L., HoW.G., NimerS.D.Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with preleukemic syndrome. J Clin Oncol.1989; 7: 1637–1645.
21.
KarasziE., JakabK., HomolyaL.Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. Br J Haematol.2001; 112: 308–314.
22.
SchaichM., RitterM., IllmerT.Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol.2001; 112: 300–307.
23.
TsujiK, MotojiT., SugawaraI.Significance of lung resistance-related protein in the clinical outcome of acute leukaemic patients with reference to P-glycoprotein. Br J Haematol.2000; 110: 370–378.
24.
ChesonB.D., CassilethP.A., HeadD.R.Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol.1990; 8: 813–819.
25.
MayerR.J., DavisR.B., SchifferC.A.Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med.1994; 331: 896–903.
26.
ReesJ.K., GrayR.G., SwirskyD.Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet.1986; 2: 1236–1241.
27.
BuchnerT., UrbanitzD.Multicentre study on intensified remission induction therapy for acute myeloid leukemia. Leuk Res.1982; 6: 827–831.
28.
LeeE.J., GeorgeS.L., CaligiuriM.Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B Study 9420. J Clin Oncol.1999; 17: 2831–2839.
29.
BaerM.R., GeorgeS.L., DodgeR.K.Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood.2002; 100: 1224–1232.
30.
VoglerW.R., Velez-GarciaE., WeinerR.S.A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol.1992; 10: 1103–1111.
31.
WiernikP.H., BanksP.L., CaseD.C.Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood.1992; 79: 313–319.
32.
ReiffersJ., HuguetF., StoppaA.M.A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia.1996; 10: 389–395.
33.
RoweJ.M., NeubergD., FriedenbergW.A phase III study of daunorubicin vs idarubicin vs mitoxantrone for older adult patients (>55 yrs) with acute myelogenous leukemia (AML): a study of the Eastern Cooperative Oncology Group (E3993). Blood.1998; 92: 1284. Abstract.
34.
ArchimbaudE., JehnU., ThomasX.Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem transplantation in elderly patients with acute myeloid leukemia. Leukemia.1999; 13: 843–849.
35.
StoneR.M., BergD.T., GeorgeS.L.Post-remission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone/intermediate dose cytarabine with standard dose cytarabine. Blood.2001; 98: 548–553.
36.
ZittounR.A., MandelliF., WillemzeR.Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia: European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med.1995; 332: 217–223.
37.
HarousseauJ.L., CahnJ.Y., PignonB.Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adults acute myeloid leukemia: the Groupe Ouest Est Leucemies Aigues Myeloblastiques. Blood.1997; 90: 2978–2986.
38.
CassilethP.A., HarringtonD.P., AppelbaumF.R.Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med.1998; 339: 1649–1656.
39.
DeegH.J., ShulmanH.M., AndersonJ.E.Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood.2000; 95: 1188–1194.
40.
PeggsK., CraddockC., MilliganD.Non-myeloablative allogeneic transplantation for high-risk acute leukemia and myelodysplasia. Blood.2001; 98: 1722.
41.
LowenbergB., ZittounR., KerkhofsH.On the value of intensive-remission induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer leukemia Group. J Clin Oncol.1989; 7: 1268–1274.
42.
OhnoR., TomonagaM., KobayashiT.Effect of granulocyte colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med.1990; 323: 871–877.
43.
RoweJ.M., AndersenJ.W., MazzaJ.J.A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood.1995; 86: 457–462.
44.
StoneR.M., BergD.T., GeorgeS.L.Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia: Cancer and Leukemia Group B. N Engl J Med.1995; 332: 1671–1677.
45.
LowenbergB., SuciuS., ArchimbaudE.Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood.1997; 90: 2952–2961.
46.
WitzF., SadounA., PerrinM.C.A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients: Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood.1998; 91: 2722–2730.
47.
BolamS., HamblinT.Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia. Drugs Aging.1999; 15: 451–460.
48.
HeilG., HoelzerD., SanzM.A.A randomized, double-blind, placebo-controlled phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia: the International Acute Myeloid Leukemia Study Group. Blood.1997; 90: 4710–4718.
49.
LarsonR.A., DodgeR.K., LinkerC.A.A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood.1998; 92: 1556–1564.
50.
Uyl-de GrootC.A., LowenbergB., VellengaE.Cost-effectiveness and quality of life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol.1998; 100: 629–636.
51.
ListA.F., KopeckyK.J., WillmanC.L.Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood.2001; 98: 3212–3220.
52.
BrossP.F., BeitzJ., ChenG.Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res.2001; 7: 1490–1496.
53.
EsteyE.H., ThallP.F., GilesF.J.Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood.2002; 99: 4343–4349.
54.
De AngeloD.J., SchifferC., StoneR.Interim analysis of a phase I study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients <60 years old with untreated acute myeloid leukemia. Blood.2002; 100: 198a–199a.
55.
KarpJ.E., LancetJ.E., KaufmannS.H.Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood.2001; 97: 3361–3369.
56.
YokotaS., KiyoiH., NakaoM.Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematologic malignancies: a study of a large series of patients and cell lines. Leukemia.1997; 11: 1605–1609.
57.
MeshinchiS., WoodsW.G., StirewaltD.L.Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood.2001; 97: 89–94.
58.
SmithB.D., LevisM.Brown P, et al. Single agent CEP-701, a novel FLT-3 inhibitor, shows initial response in patients with refractory acute myeloid leukemia. Blood.2002; 100: 314a.
59.
StoneR.M., KlimekV., DeAngeloD.J.PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): a phase II clinical trial. Blood.2002; 100: 316a.
